Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D and denosumab for bone mineral metabolism in maintenance hemodialysis
ChiCTR2500099025Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of denosumab and vitamin d in end-stage kidney disease (ESKD), uremia, secondary hyperparathyroidism (SHPT) and 2 more (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Vascular Calcification Score. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
denosumabvitamin d
03
Conditions
end-stage kidney disease (ESKD)uremiasecondary hyperparathyroidism (SHPT)chronic kidney disease-mineral and bone disorder (CKD-MBD)osteoporosis
Beyond the preview
Go deeper on ChiCTR2500099025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099025.